Search
sacituzumab govitecan-hziy (Trodelvy)
Indications:
- triple-negative metastatic breast cancer*
* previously treated with at least two other cancer regimens
Contraindications:
- pregnancy
Adverse effects:
- most common
- nausea, neutropenia, diarrhea, fatigue, anemia, vomiting, alopecia, constipation, decreased appetite, rash, abdominal pain
* boxed warning
- risk of severe neutropenia (monitor, consider fligrastim)
Mechanism of action:
- trop-2 directed antibody & topoisomerase inhibitor drug conjugate
Notes:
- progression-free survival 5.6 months vs 1.7 months for single agent chemotherapy in women without brain metastases [2]
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
antineoplastic monoclonal antibody
References
- FDA News Release. April 22, 20202
FDA Approves New Therapy for Triple Negative Breast Cancer
That Has Spread, Not Responded to Other Treatments.
https://www.fda.gov/news-events/press-announcements/fda-approves-new-therapy-triple-negative-breast-cancer-has-spread-not-responded-other-treatments
- Bardia A, Hurvitz SA, Tolaney SM et al
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
N Engl J Med. 2021 Apr 22;384(16):1529-1541
PMID: 33882206
https://www.nejm.org/do/10.1056/NEJMdo005998/full/